High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010

Elisabeth Sanchez-Padilla, Themba Dlamini, Alexandra Ascorra, Sabine Rüsch-Gerdes, Zerihun Demissie Tefera, Philippe Calain, Roberto de la Tour, Frauke Jochims, Elvira Richter, Maryline Bonnet, Elisabeth Sanchez-Padilla, Themba Dlamini, Alexandra Ascorra, Sabine Rüsch-Gerdes, Zerihun Demissie Tefera, Philippe Calain, Roberto de la Tour, Frauke Jochims, Elvira Richter, Maryline Bonnet

Abstract

In Africa, although emergence of multidrug-resistant (MDR) tuberculosis (TB) represents a serious threat in countries severely affected by the HIV epidemic, most countries lack drug-resistant TB data. This finding was particularly true in the Kingdom of Swaziland, which has the world's highest HIV and TB prevalences. Therefore, we conducted a national survey in 2009-2010 to measure prevalence of drug-resistant TB. Of 988 patients screened, 420 new case-patients and 420 previously treated case-patients met the study criteria. Among culture-positive patients, 15.3% new case-patients and 49.5% previously treated case-patients harbored drug-resistant strains. MDR TB prevalence was 7.7% and 33.8% among new case-patients and previously treated case-patients, respectively. HIV infection and past TB treatment were independently associated with MDR TB. The findings assert the need for wide-scale intervention in resource-limited contexts such as Swaziland, where diagnostic and treatment facilities and health personnel are lacking.

Figures

Figure 1
Figure 1
Tuberculosis diagnosis facilities (red diamonds), Swaziland.
Figure 2
Figure 2
Study profile, national drug-resistant tuberculosis (TB) survey, Swaziland, 2009–2010. A) New patients; B) previously treated patients. NRL, National Reference Laboratory; MTB, Mycobacterium tuberculosis; MOTT, mycobacteria other than tuberculosis. *MTB + MOTT. †1 MTB + MOTT, 2 MTB + other bacteria (nonmycobacteria).

References

    1. World Health Organization. Global tuberculosis control. Geneva: The Organization; 2010.
    1. World Health Organization. The stop TB strategy: building on and enhancing DOTS to meet the TB related millennium development goals. Geneva: The Organization; 2006.
    1. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059–64. 10.1016/S0140-6736(02)08904-3
    1. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th edition. Geneva: The Organization; 2009.
    1. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: The Organization; 2011.
    1. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: November 2009. Geneva: The Programme; 2009.
    1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing. Geneva: The Organization; 2009.
    1. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80. 10.1016/S0140-6736(06)69573-1
    1. Ministry of Health and Social Welfare. Report of the rapid survey for the detection of extreme drug resistant tuberculosis in the Kingdom of Swaziland. Swaziland; 2008.
    1. World Health Organization. Treatment of tuberculosis: guidelines. 4th ed. Geneva: The Organization; 2010.
    1. World Health Organization. 7th meeting of the strategic and technical advisory group for tuberculosis (STAG-TB). Report on conclusions and recommendations. Geneva: The Organization; 2007.
    1. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, Hanekom M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis. 2010;16:264–71.
    1. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995;332:336–7. 10.1056/NEJM199502023320518
    1. Suchindran S, Brouwer ES, Van RA. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS ONE. 2009;4:e5561. 10.1371/journal.pone.0005561
    1. Wright A, Zignol M, Van DA, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009;373:1861–73. 10.1016/S0140-6736(09)60331-7
    1. Centers for Disease Control and Prevention. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons—Florida and New York, 1988–1991. MMWR Morb Mortal Wkly Rep. 1991;40:585–91.
    1. Rullán JV, Herrera D, Cano R, Moreno V, Godoy P, Peiro EF, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis. 1996;2:125–9. 10.3201/eid0202.960208
    1. Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus–infected patients in a South African hospital. Clin Infect Dis. 1999;29:96–101. 10.1086/520189
    1. Glynn JR, Whiteley J, Bifani PJ, Kremer K. van SD. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis. 2002;8:843–9.
    1. Pardini M, Niemann S, Varaine F, Iona E, Meacci F, Orru G, et al. Characteristics of drug-resistant tuberculosis in Abkhazia (Georgia), a high-prevalence area in Eastern Europe. Tuberculosis (Edinb). 2009;89:317–24. 10.1016/j.tube.2009.04.002
    1. Affolabi D, Anyo G, Faihun F, Sanoussi N, Shamputa IC, Rigouts L, et al. First molecular epidemiological study of tuberculosis in Benin. Int J Tuberc Lung Dis. 2009;13:317–22.
    1. Cowley D, Govender D, February B, Wolfe M, Steyn L, Evans J, et al. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin Infect Dis. 2008;47:1252–9. 10.1086/592575
    1. Homolka S, Post E, Oberhauser B, George AG, Westman L, Dafae F, et al. High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone. BMC Microbiol. 2008;8:103. 10.1186/1471-2180-8-103
    1. Kibiki GS, Mulder B, Dolmans WM, de Beer JL, Boeree M, Sam N, et al. M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania. BMC Microbiol. 2007;7:51. 10.1186/1471-2180-7-51
    1. Viegas SO, Machado A, Groenheit R, Ghebremichael S, Pennhag A, Gudo PS, et al. Molecular diversity of Mycobacterium tuberculosis isolates from patients with pulmonary tuberculosis in Mozambique. BMC Microbiol. 2010;10:195. 10.1186/1471-2180-10-195
    1. Groenheit R, Ghebremichael S, Svensson J, Rabna P, Colombatti R, Riccardi F, et al. The Guinea-Bissau family of Mycobacterium tuberculosis complex revisited. PLoS ONE. 2011;6:e18601. 10.1371/journal.pone.0018601
    1. Johnson R, Warren RM, van der Spuy GD, Gey van Pittius NC, Theron D, Streicher EM, et al. Drug-resistant tuberculosis epidemic in the Western Cape driven by a virulent Beijing genotype strain. Int J Tuberc Lung Dis. 2010;14:119–21.
    1. Strategic and Technical Advisory Group for Tuberculosis (STAG-TB). Report of the ninth meeting. Geneva: The Organization; 2009.
    1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. Geneva: The Organization; 2008.
    1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15. 10.1056/NEJMoa0907847
    1. Cohen T, Colijn C, Finklea B, Wright A, Zignol M, Pym A, et al. Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study. PLoS ONE. 2008;3:e2363. 10.1371/journal.pone.0002363
    1. Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;177:1302–6. 10.1164/rccm.200801-175PP
    1. Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N. Underreported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14:1345–52. 10.3201/eid1409.061524

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다